GRNDaD: big data and sickle cell disease
GRNDaD: big data and sickle cell disease GRNDaD: big data and sickle cell disease
More episodes
-
GRNDaD: big data and sickle cell disease
-
Investigational curative gene therapy approaches to sickle cell disease
-
Why is AAV FVIII gene therapy not approved by the US Food and Drug Administration yet?
-
Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding
-
Concizumab: a novel anti-TFPI therapeutic for hemophilia
-
Naive T-cell depletion in stem cell transplantation
-
The management of venous thromboembolism in hospitalized patients with COVID-19
-
Gene therapy for hemophilia: anticipating the unexpected
-
The changing landscape of anticoagulation in cancer-associated thrombosis
-
TA-TMA: state of the art for diagnosis and treatment
-
Inherited predisposition to myeloid malignancies
-
Managing patients who are receiving warfarin (or DOAC)and need an elective surgery or procedure
-
Daily light-and-darkness onset regulates mouse hematopoietic stem cells
-
Extended therapy for unprovoked venous thromboembolism: when is it indicated?
-
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances
-
Challenges facing the benign hematology physician-scientist workforce
-
Choosing for whom to recommend allogeneic transplantation for AML in CRL
-
Catalyzing innovation in clinical trial design and analysis at NHLBI
-
ITP and thrombosis: an intriguing association
-
The current therapeutic landscape of FLT3 inhibitors
-
How many mice? Design considerations for murine studies
-
The Direct Oral Anticoagulants – can we finally stop using rat poison?
-
Impact of the ICAL on the treatment of acute leukemia
-
Venetoclax: a primer
-
Technological Solutions For Global Hematology And Oncology